Months after beginning a $4 billion savings strategy, Pfizer is planning on a new $1.5 billion round of cost cuts, as well as what are likely to be more reductions in the future.
The cuts include shrinking the company’s manufacturing base, a Pfizer spokesperson said, a portion of Pfizer’s business which grew substantially during the Covid-19 pandemic. “This program will focus on streamlining our ways of working, reducing complexity, and increasing productivity in Pfizer Global Supply,” the spokesperson said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.